RareCan is an organization focused on enhancing research and improving outcomes for individuals with rare forms of cancer. It operates a direct-to-patient clinical trial platform that aims to expedite the processes involved in cancer research. By developing innovative patient and data pipelines, supported by proprietary technology, RareCan facilitates quicker and more cost-effective access for the pharmaceutical industry to the necessary patients and data. This initiative is designed to accelerate the development of precision medicine trials, thereby increasing the likelihood of successful outcomes in rare cancer treatments and ultimately contributing to the advancement of new therapies in the global cancer drug market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.